SAMβA(βIIPKC624-632) is a 9-amino-acid peptide(sequence: RNAENFDRF) which is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. SAMβA may be a potential treatment for patients with heart failure. Treatment of cultured neonatal cardiac myocytes with SAMβA prevented mitochondrial fragmentation triggered by angiotensin II. SAMβA reduced the excessive association of βIIPKC with Mfn1 induced by angiotensin II in cardiac myocytes, as measured by co-immunoprecipitation. The treatment of cardiac neonatal myocytes with SAMβA had a better effect in protecting against H2O2-induced metabolic dysfunction when compared to the global βIIPKC inhibitor, βIIV5-3.
Ferreira, J. C. B., Campos, J. C., Qvit, N., Qi, X., Bozi, L. H. M., Bechara, L. R. G., u2026 Mochly-Rosen, D. (2019). A selective inhibitor of mitofusin 1-u03b2IIPKC association improves heart failure outcome in rats. Nature Communications, 10(1). https://doi.org/10.1038/s41467-018-08276-6